NCT00233454 - Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

June 18, 2010

Study Completion Date

April 16, 2011

Conditions

Systemic Mastocytosis, Aggressive (ASM)Leukemia, Mast CellHematological Non-mast Cell Lineage Disease (AHNMD)

Interventions

DRUG

Midostaurin

Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR

Trial Locations (3)

63110

Washington University-St. Louis, St Louis

94305

Stanford University School of Medicine, Stanford

02115

Dana Farber Cancer Institute, Boston